Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
  • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
  • C07D491/10—Spiro-condensed systems
  • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
  • A61K31/404—Indoles, e.g. pindolol
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
  • C07D209/32—Oxygen atoms
  • C07D209/34—Oxygen atoms in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
  • C09B67/0025—Crystal modifications; Special X-ray patterns
• • C—CHEMISTRY; METALLURGY
  • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
  • C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
  • C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
  • C09B67/0096—Purification; Precipitation; Filtration
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to pharmaceutical compositions, more particularly a novel crystalline form of meisoindigo, methods of preparation, and methods of preventing cancer, treating cancer, or treating inflammatory-related diseases associated with inhibiting cyclin-dependent kinases, pro-inflammatory cytokine expression, or reduced expression of anti-inflammatory cytokines.
• Tumor cells are characterized by uncontrolled cell proliferation due to the loss of the integration and coordination of extracellular signals with the cell cycle machinery.
• a typical cell cycle is classified into Gl, S, G2 and M phases.
• proliferation is controlled in the Gl phase of the cell cycle.
• cells can have different destinies. Examples of these cell destinies include: 1) leaving the cell cycle and entering a reversible quiescence phase; 2) exiting cell cycle and undergoing apoptosis; 3) differentiating and irreversibly exiting from the cell cycle; and 4) passing through the restriction point and becoming largely independent of extracellular signals and progress automatically through subsequent cell cycle phases (S, G2, M) to the next Gl phase.
• Cyclins are a remarkably diverse family of proteins, which are synthesized from the mid/late of G1 phase until the M phase of the cell cycle and then rapidly degraded.
• a CDK typically contains a catalytic domain of 300 amino acids, which is inactive by itself.
• Cdks become active by binding to a cyclin.
• the activity of cdks is inhibited by their endogenous inhibitors (CDK inhibitors, or cdkls include pl5/pl6/pl8/pl9 and p21/p27).
• CDK inhibitors or cdkls include pl5/pl6/pl8/pl9 and p21/p27).
• Specific cyclin/CDK complexes are formed at specific stages of the cell cycle, and their activities are required for progression of the cell cycle through S phase and mitosis.
• CDKs Over-activation of CDKs is a character of a majority of human tumor cells.
• Strategies have been developed to modulate CDK activity for therapeutic intervention by either directly targeting the catalytic CDK Subunit or indirectly affecting the CDK regulatory pathways 3).
• Small molecule CDK inhibitors were designed to interact specifically with the ATP binding site of CDKs, such as flavopiridol congeners, poly sulfates, toyocamycin derivatives, etc. Anticancer effects have been shown in clinical trials for those agents. Modulation of CDK activities can be achieved by regulating the phosphorylation of CDKS or altering the expression of the CDKs or their inhibitors (CDKIs). It is difficult to find specific modulators that do not interfere with other cell cycle components and do not affect normal cells.
• the present invention provides a novel crystal form (solid form) of Meisoindigo (Crystal Form I), which exhibits excellent therapeutic efficacy against various autoimmune diseases/inflammatory diseases as well as cancers.
• the present invention further provides a process for preparing the crystal form (Form 1) as well as pharmaceutical compositions and dosages comprising the novel crystal form.
• the present invention provides a solid form of N- methylisoindigo or a solid crystal form of N-methylisoindigo (Crystal Form I) having an X- ray powder diffraction pattern comprising a peak, in terms of 2-theta, at about 7.71°.
• the solid form or solid crystal form has an X-ray powder diffraction pattern comprising peaks, in terms of 2-theta, at about 7.71°, about 17°, about 18°, and about 29°.
• the solid form or solid crystal form has an X-ray powder diffraction pattern substantially as shown in FIG. 5.
• the solid form or solid crystal form has an infrared spectrum of N-methylisoindigo substantially as shown in FIG. 1. In other aspects, the solid form or solid crystal form has an NMR spectrum of N-methylisoindigo substantially as shown in FIG. 2.
• the solid form or solid crystal form has a differential scanning calorimetry (DSC) thermogram comprising an endothermic peak at about 235°C to 237°C.
• the solid form or solid crystal form has a differential scanning calorimetry (DSC) thermogram substantially as shown in Table 1.
• the solid form or solid crystal form has a particle size distribution with an average particle size d50 below 25 pm. In certain embodiments, the solid form or solid crystal form has a particle size distribution with an average particle size d50 below 25 pm, below 24 pm, below 23 pm, below 22 pm, below 21 pm, below 20 pm, below 19 pm, below 18 pm, below 17 pm, or below 16 pm. In other embodiments, the solid form or solid crystal form has a particle size distribution with an average particle size d50 of between 1 pm and 25 pm (e.g., between 1 pm and 25 pm, between 1 pm and 20 pm, between 5 pm and 25 pm, between 5 pm and 20 pm, between 10 pm and 25 pm, or between 10 pm and 20 pm).
• 1 pm and 25 pm e.g., between 1 pm and 25 pm, between 1 pm and 20 pm, between 5 pm and 25 pm, between 5 pm and 20 pm, between 10 pm and 25 pm, or between 10 pm and 20 pm.
• the solid form or solid crystal form has a particle size distribution ratio (d90-dl0)/d50 of less than 2.50.
• the particle size distribution ratio (d90-dl0)/d50 is less than 2.50, less than 2.40, less than 2.30, less than 2.20, less than 2.10, less than 2.00, or less than 1.90.
• the solid form or solid crystal form has a maximum particle size below 100 pm.
• the maximum particle size is below 100 pm, below 90 pm, below 80 pm, below 70 pm, below 60 pm, or below 50 pm.
• the particle size distribution facilitates pharmaceutical processing during formulation of the solid form or solid crystal form. In other aspects, the particle size distribution enhances the stability and bioavailability of the solid form or solid crystal form. [0018] In some embodiments, the present invention provides a pharmaceutical composition comprising a solid form or solid crystal form disclosed herein, and a pharmaceutically acceptable carrier.
• the solid form or solid crystal form is present in the pharmaceutical composition in an amount of at least about 90% by weight. In other embodiments, the solid form or solid crystal form is present in the pharmaceutical composition in an amount of at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, or at least about 90% by weight.
• the solid form or solid crystal form is present in the pharmaceutical composition in an amount of between 1% by weight and 90% by weight (i.e., between 1% by weight and 90% by weight, between 1% by weight and 80% by weight, between 1% by weight and 70% by weight, between 1% by weight and 60% by weight, between 1% by weight and 50% by weight, between 1% by weight and 40% by weight, between 1% by weight and 30% by weight, between 1% by weight and 20% by weight, or between 1% by weight and 10% by weight).
• 1% by weight and 90% by weight i.e., between 1% by weight and 90% by weight, between 1% by weight and 80% by weight, between 1% by weight and 70% by weight, between 1% by weight and 60% by weight, between 1% by weight and 50% by weight, between 1% by weight and 40% by weight, between 1% by weight and 30% by weight, between 1% by weight and 20% by weight, or between 1% by weight and 10% by weight.
• the solid form or solid crystal form is substantially purified. In other aspects, solid form or solid crystal form is crystalline.
• the present invention provides a process for preparing a solid form or solid crystal form disclosed herein, the process comprising precipitating a crystalline form from a solution comprising an organic solvent.
• the solution comprises glacial acetic acid.
• the solution further comprises N-methylisatin, oxindole, and/or HC1.
• the present invention provides a solid form or a solid crystal form of N-methylisoindigo prepared by a process disclosed herein and recrystallized in any other acceptable organic solvent, and preferably in glacial acetic acid.
• the present invention provides a method of treating cancer, comprising administering a solid form or solid crystal form of N-methylisoindigo disclosed herein or a pharmaceutical composition disclosed herein to a patient in need thereof.
• the present invention provides a method of treating an inflammatory-related disease associated with cytokine expression levels, comprising administering a solid form or solid crystal form of N-methylisoindigo disclosed herein or a pharmaceutical composition disclosed herein to a patient in need thereof.
• the present invention provides a pharmaceutical composition consisting essentially of a solid form or solid crystal form of N-methylisoindigo disclosed herein.
• FIG. 1 is an infrared spectrum of N-methylisoindigo.
• FIG. 2 is an NMR spectrum of N-methylisoindigo.
• FIG. 3 is a mass spectrum of N-methylisoindigo (positive Q1 scan).
• FIG. 4 is a mass spectrum of N-methylisoindigo (negative Q1 scan).
• FIG. 5 shows a comparison of the X-ray powder diffraction patterns. Unsmoothed XRD data for the four N-methylisoindigo samples. The peak of ⁇ 40,000 counts at 7.71 deg is truncated so that a detailed view of the data in the range 5 ⁇ 2Theta ⁇ 55 deg is possible. Note the extra peaks in sample 0501 (blue curve) that is further detailed in FIG. 6 and Table 2.
• FIG. 8 is an example of ' H-NMR spectrum of samples 1 to 6 N-methylisoindigo.
• FIG. 9 is an example of 13 C-NMR spectrum of samples 1 to 6 N-methylisoindigo.
• FIG. 10A shows a comparison of the X-ray powder diffraction patterns for samples 1 to 6. Individual X-ray powder diffractions patterns for sample 1, 2, 3, 4, 5, and 6 are presented in FIGs. 10B, IOC, 10D, 10E, 10F, and 10G, respectively.
• FIG. 11 shows examples of particle sizes and their distribution of Crystal Form I of meisoindigo. DETAILED DESCRIPTION OF THE INVENTION
• Crystal Form I a novel and unique crystal form
• a method of manufacturing crystalline N-methylisoindigo that has shown excellent efficacy in treating various autoimmune/inflammatory diseases and cancers.
• the present invention provides a solid form of N- methylisoindigo or a solid crystal form of N-methylisoindigo having an X-ray powder diffraction pattern substantially as shown in FIG. 10A.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. 10B.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. IOC.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. 10D.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. 10E.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. 10F.
• the solid form of N- methylisoindigo or solid crystal form of N-methylisoindigo has an X-ray powder diffraction pattern substantially as shown in FIG. 10G.
• the solid form or solid crystal form has an NMR spectrum of N- methylisoindigo substantially as shown in FIG. 8 and/or FIG. 9.
• the solid form or solid crystal form is in the form of a pharmaceutical composition or formulation which is ready for use to be administered to a patient or patient in need thereof.
• the solid form or solid crystal form may be administered by the oral, intravenous, topical, local installations, mtraperitoneal or nasal route.
• Said compositions can be utilized to achieve the desired pharmacological effect by administration to a patient in need thereof.
• a patient for the purpose of this invention, is a mammal, including a human, in need of treatment for the particular condition or disease. Therefore, the present invention includes pharmaceutical compositions that are comprised of a pharmaceutically acceptable carrier and a pharmaceutically effective amount of the solid form or solid crystal form.
• a pharmaceutically acceptable carrier is preferably a carrier that is relatively nontoxic and innocuous to a patient at concentrations consistent with effective activity of the active ingredient so that any side effects ascribable to the carrier do not vitiate the beneficial effects of the solid form or solid crystal form.
• a pharmaceutically effective amount of a solid form or solid crystal form is preferably that amount which produces a result or exerts an influence on the particular condition being treated.
• the solid form or solid crystal form of the present invention can be administered with pharmaceutically -acceptable carriers well known in the art using any effective conventional dosage unit forms, including immediate, slow and tuned release preparations, orally, parenterally, topically, nasally, ophthalmically, optically, sublingually, rectally, vaginally, and the like.
• the compounds according to the invention can have systemic and-' or local activity.
• they can be administered in a suitable manner, such as, for example, via the oral, parenteral, pulmonary', nasal, sublingual, lingual, buccal, rectal, vaginal, dermal, transdermal, conjunctival, otic route or as an implant or stent.
• the compounds according to the invention for oral administration, it is possible to formulate the compounds according to the invention to dosage forms known in the art that deliver the compounds of the invention rapidly and/or in a modified manner, such as, for example, tablets (uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble), orally-disintegrating tablets, fdms/wafers, films/lyophylisates, capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions it is possible to incorporate the compounds according to the invention in crystalline and/or amorphised and/or dissolved form into said dosage forms.
• tablets uncoated or coated tablets, for example with enteric or controlled release coatings that dissolve with a delay or are insoluble
• orally-disintegrating tablets for example, fdms/wafers, films/lyophylisates
• capsules for example hard
• Parenteral administration can be effected with avoidance of an absorption step (for example intravenous, intraarterial, mtracardial, iniraspinal or intralumhal) or with inclusion of absorption (for example intramuscular, subcutaneous, intraeutaneous, percutaneous or mtraperitonea!).
• Administration forms which are suitable for parenteral administration are, inter alia, preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophylisates or sterile powders.
• Examples which are suitable for other administration routes are pharmaceutical forms for inhalation [inter alia powder inhalers, nebulizers], nasal drops, nasal solutions, nasal sprays; iablets/fdrns/ wafers/capsules for lingual, sublingual or buccal administration; suppositories; eye drops, eye ointments, eye baths, ocular inserts, ear drops, ear sprays, ear powders, ear-rinses, ear tampons, vaginal capsules, aqueous suspensions (lotions, mixturae agitandae), lipophilic suspensions, emulsions, ointments, creams, transderma! therapeutic systems (such as, for example, patches), milk, pastes, foams, dusting powders, implants or stents
• Tins can be effected in a manner known per se by mixing with pharmaceutically suitable excipients.
• Pharmaceutically suitable excipients include, inter alia,
• fillers and carriers for example cellulose, microcrystalline cellulose (such as, for example, Avieel”), lactose, mannitol, starch, calcium phosphate (such as, for example, Di-Cafos * )), ⁇ ointment bases (for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment polyethylene glycols),
• ⁇ ointment bases for example petroleum jelly, paraffins, triglycerides, waxes, wool wax, wool wax alcohols, lanolin, hydrophilic ointment polyethylene glycols
• bases for suppositories for example polyethylene glycols, cacao butter, hard fat
• solvents for example water, ethanol, isopropanol, glycerol, propylene glycol, medium chain-length triglycerides fatly oils, liquid polyethylene glycols, paraffins
• surfactants, emulsifiers, dispersants or welters for example sodium dodecy! sulfate), lecithin, phospholipids, fatty alcohols (such as, for example, Lanette * ), sorbitan fatty acid esters (such as, for example, Span”), polyoxyethylene sorbitan fatty acid esters (such as, for example, Tween ), polyoxyethylene fatty acid glycerides (such as, for example, Cremophor * ), polyoxethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, glycerol fatty acid esters, poioxamers (such as, for example, Pluronic ),
• buffers for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
• acids and bases for example phosphates, carbonates, citric acid, acetic acid, hydrochloric acid, sodium hydroxide solution, ammonium carbonate, trometamol, triethanolamine
• viscosity-increasing agents for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethyieeilulose, hydroxypropyl- cellulose, carboxymethylcellulose-sodiiim, starch, carbomers, polyacrylic acids (such as, for example, Carbopol * ); alginates, gelatine),
• binders for example polyvinylpyrrolidone, methylcellulose, hydroxypropylmethyieeilulose, hydroxypropyl- cellulose, carboxymethylcellulose-sodiiim, starch, carbomers, polyacrylic acids (such as, for example, Carbopol * ); alginates, gelatine),
• disintegrants for example modified starch, carboxymethyl cellulose-sodium, sodium starch glyeolate (such as, for example, Expiotab ), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSof )
• modified starch carboxymethyl cellulose-sodium, sodium starch glyeolate (such as, for example, Expiotab ), cross- linked polyvinylpyrrolidone, croscarmellose-sodium (such as, for example, AcDiSof )
• lubricants for example magnesium stearate, stearic acid, talc, highly-disperse silicas (such as, for example, Aerosif)
• coating materials for example sugar, shellac
• film formers for films or diffusion membranes which dissolve rapidly or in a modified manner for example polyvinylpyrrolidones (such as, for example, Kollidon ), polyvinyl alcohol, hydroxypropylmethylcellulose, hydroxypropylcellulose, ethyl cellulose, hydroxypropyl- metliylcellulose phthalate, cellulose acetate, cellulose acetate phthalate, polyaci ates, polymethacrylates such as, for example, Eudragit * )), ⁇ capsule materials (for example gel atine, h droxypropylmethylcellulose),
• synthetic polymers for example polylactides, polyglycoiides, polyacrylates, polymethacrylates (such as, for example, Eudragit * ), polyvinylpyrrolidones (such as, for example, Kollidon ), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and bl ockcopoly mers), ⁇ plasticizers (for example polyethylene glycols, propylene glycol, glycerol, triacetine, triacetyl citrate, dibutyl phthalate), penetration enhancers,
• synthetic polymers for example polylactides, polyglycoiides, polyacrylates, polymethacrylates (such as, for example, Eudragit * ), polyvinylpyrrolidones (such as, for example, Kollidon ), polyvinyl alcohols, polyvinyl acetates, polyethylene oxides, polyethylene glycols and their copolymers and b
• stabilisers for example antioxidants such as, for example, ascorbic acid, ascorbyl paimitate, sodium ascorbate, buiylhydroxyamsoie, butylhydroxytoluene, propyl gal late
• ⁇ preservatives for example parabens, sorbic acid, thiomersal, benza!konium chloride, chlorhexidine acetate, sodium benzoate
• colorants for example inorganic pigments such as, for example, iron oxides, titanium d oxide
• flavorings sweeteners, flavor- and/or odor-masking agents.
• the present invention furthermore relates to pharmaceutical compositions which comprise the crystalline forms of N-methylisoindigo disclosed herein, conventionally together with one or more pharmaceutically suitable excipient(s), and to their use according to the present invention.
• Irregular and/or abnormal inflammation is a major component of a wide range of human diseases. People suffering from multiple degenerative disorders often exhibit excess levels of pro-inflammatory markers in their blood.
• pro-inflammatory markers is pro-inflammatory mark cytokines including IL-la, b, IL-2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF-a, LT, LIF, Oncostatin, and IFNcla, b, g.
• a non-limiting list of common medical problems that are directly caused by inflammatory cytokines include: arthritis where inflammatory cytokines destroy lead to lesion in the synovial membrane and destruction of joint cartilage and bone; kidney failure where inflammatory cytokines restrict circulation and damage nephrons; lupus wherein inflammatory cytokines induce an autoimmune attack; asthma where inflammatory cytokines close the airway; psoriasis where inflammatory cytokines induce dermatitis; pancreatitis where inflammatory cytokines induce pancreatic cell injury; allergy where inflammatory cytokines induce autoimmune reactions; fibrosis where inflammatory cytokines attack traumatized tissue; surgical complications where inflammatory cytokines prevent healing; anemia where inflammatory cytokines attack erythropoietin production; and fibromyalgia where inflammatory cytokines are elevated in fibromyalgia patients.
• Other diseases associated with chronic inflammation include cancer, which is caused by chronic inflammation; heart attack where chronic inflammation contributes to coronary atherosclerosis; Alzheimer's disease where chronic inflammation destroys brain cells; congestive heart failure where chronic inflammation causes heart muscle wasting; stroke where chronic inflammation promotes thrombo-embolic events; and aortic valve Stenosis where chronic inflammation damages heart Valves.
• Arteriosclerosis, osteoporosis, Parkinson's disease, infection, inflammatory bowel disease including Crohn’s disease and ulcerative colitis as well as multiple sclerosis (a typical autoimmune inflammatory-related disease) are also related to inflammation. Some diseases in advanced stages can be life- threatening.
• Several methodologies are available for the treatment of such inflammatory diseases; the results, however, are generally unsatisfactory as evidenced by a lack of efficacy and drug-related side effects associated therewith.
• IBD Inflammatory bowel disease
• CD Crohn’s disease
• UC ulcerative colitis
• IBD can involve either or both small and large bowel.
• CD can involve any part of the gastrointestinal tract, but most frequently involves the distal small bowel and colon. It either spares the rectum or causes inflammation or infection with drainage around the rectum.
• UC usually causes ulcers in the lower part of the large intestine, often starting at the rectum. Symptoms vary but may include diarrhea, fever, and pain. Patients with prolonged UC are at an increased risk of developing colon cancer.
• IBD treatments aim at controlling inflammatory symptoms, conventionally using cortical steroids, aminosalicylates and standard immunosuppressive agents such as azathioprine (6-mercaptopurine), methotrexate and cyclosporine.
• azathioprine (6-mercaptopurine)
• methotrexate a standard immunosuppressive agent
• the only disease- modifying therapies are the immunosuppressive agents: azathioprine and methotrexate, both of which have a slow onset of action and only moderate efficacy.
• Long-term therapy may cause liver damage (fibrosis or cirrhosis) and bone marrow suppression. Also, patients often become refractory to such treatment. Other therapeutic regimes merely address symptoms.
• Psoriasis is one of the most common immune-mediated chronic skin diseases that come in different forms and varied levels of severity, affecting approximately 2% or more than 4.5 million people in the United States of which 1.5 million are considered to have a moderate to severe form of the disease.
• Ten to thirty percent of patients with psoriasis also develop a form of arthritis— Psoriatic arthritis, which damages the bone and connective tissue around the joints.
• Psoriasis appears as patches of raised red skin covered by a flaky white buildup. It may also have a pimple-ish (pustular psoriasis) or burned (erythrodermic) appearance. Psoriasis may also cause intense itching and burning. Patients suffer psychologically as well as physically.
• drugs prescribed for psoriasis include those TNF-a inhibitors initially used for rheumatoid arthritis (RA) treatment, ENBREL ® (etanercept), REMICADE ® (infliximab) and HUMIRA ® (adalimumab), and T-cell inhibitor AMEVIVE ® (alefacept) from Biogen approved in 2002 and RAPTIVA ® (efalizumab) from Genentech/Xoma approved in 2003.
• RA rheumatoid arthritis
• ENBREL ® etanercept
• REMICADE ® infliximab
• HUMIRA ® adalimumab
• AMEVIVE ® alefacept
• RAPTIVA ® efalizumab
• AMEVIVE ® is an immunoglobulin fusion protein composed of the first extracellular domain of human LFA- 3 fused to the hinge, C(H)2 and C(H)3 domains of human IgG(l). It inhibits T cell proliferation through NK cells.
• RAPTIVA ® (efalizumab) is also known as anti-CDl la, a humanized monoclonal antibody which targets the T cell adhesion molecule, leukocyte function-associated antigen-1 (LFA-1).
• LFA-1 leukocyte function-associated antigen-1
• IAM-1 intercellular adhesion molecule-1
• T-cell inhibitors of AMEVIVE ® (alefacept) or RAPTIVA ® (efalizumab) may be more tolerable in psoriasis treatment
• these therapies act as immunosuppressive agents.
• Immunosuppressive agents have the potential to increase the risk of infection, reactivate latent, chronic infections or increase the risk of cancer development.
• Rheumatoid arthritis represents another example of troublesome inflammatory disorders. It is a common chronic inflammatory-related disease characterized by chronic inflammation in the membrane lining (the synovium) of the joints and/or other internal organs. The inflammatory cells can also invade and damage bone and cartilage. The joint involved can lose its shape and alignment, resulting in loss of movement. Patients with RA have pain, stiffness, warmth, redness, and swelling in the joint, and other systemic symptoms like fever, fatigue, and anemia. Approximately 1% of the population or 2.1 million in the U.S. are currently affected, of which more are women (1.5 million) than men (0.6 million).
• RA pathology of RA is not fully understood although the cascade of improper immunological reactions has been postulated as a mechanism.
• Conventional treatment is unfortunately inefficient in RA (29).
• the disease does not respond completely too symptomatic medications including corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) used since the 1950s. Also, these medications carry a risk of serious adverse effects.
• NSAIDs non-steroidal anti-inflammatory drugs
• DMARDs disease-modifying antirheumatic drugs
• MTX Methotrexate
• a new class of biologic DMARDs (disease-modifying antirheumatic drugs) for the treatment of RA has recently been developed based on an understanding of the role of cytokines, TNF-a, and IL-1, in the inflammatory process.
• the FDA has approved several such DMARDs including ENBREL ® (etanercept) from Immunex/ Amgen Inc. in 1998, REMICADE ® (infliximab) from Centocor/Johnson & Johnson, HUMIRA ® (adalimumab) from Abbott Laboratories Inc. in 2002, and KINERET ® (anakinra) from Amgen in 2001.
• ENBREL ® is a soluble TNF receptor (TNFR) recombinant protein.
• REMICADE ® is a humanized mouse (chimeric) anti-TNF-a monoclonal antibody.
• HUMIRA ® is a fully human anti-TNF monoclonal antibody created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and human IgGEk constant regions. All these 3 protein-based drugs target and bind to TNF-a to block the effects of TNF-a.
• KINERET ® (anakinra) is a recombinant IL-1 receptor antagonist, which is similar to native human IL-IRa, except for the addition of a single methionine residue at its amino terminus KINERET ® (anakinra) blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the IL-1 type I receptor (IL-1RI) and consequently reducing the pro-inflammatory effects of IL-1.
• IL-1RI IL-1 type I receptor
• TNF-a blocking agents have similar efficacy when combined with MTX, a widely used DMARD, in the treatment of patients with RA. While providing significant efficacy and a good overall safety profile in the short and medium term in many patients with RA, these biologic treatments may create serious problems and long term side effects, such as on the liver, and still need to be evaluated. There has been a disturbing association between the use of both of ENBREL ® (etanercept) or REMICADE ® (infliximab) and the development of lymphoma.
• UCPPS urological chronic pelvic pain syndromes
• a variety of medications and therapies are available which are based solely on symptom relief. These therapies include: oral medication; bladder instillation (directly into the bladder through a thin, flexible tube inserted through the urethra) using dimethyl Sulfoxide, or instillation of a solution that contains combinations of medications such as the combination of heparin, lidocaine and Sodium bicarbonate); nerve stimulation (transcutaneous electrical nerve stimulation or TENS), using mild electrical pulses to relieve pelvic pain and, in some cases, reduce urinary frequency; bladder distention; and Surgery (bladder augmentation, fulguration, or resection).
• TENS transcutaneous electrical nerve stimulation
• Oral medications are the most convenient therapies, which are aimed at relieving pain and/or other symptoms by relaxing and protecting the bladder from irritation by means of pain relievers (Ibuprofen, and nonsteroidal anti-inflammatory drugs); tricyclic antidepressants, such as amitriptyline or imipramine; or antihistamines, like diphenhydramine and loratadine; or pentosan, a semi-synthetically produced heparin-like macromolecular carbohydrate derivative, which chemically and structurally resembles glycosaminoglycans.
• pentosan (Elmiron) is the only oral drug approved by the Food and Drug Administration (FDA) specifically for interstitial cystitis.
• Etiology of UCPPS is unknown.
• several hypotheses exist which include inflammation/autoimmunity, abnormality of cell proliferation, occult infection, genetic, chemical, neurologic, psychological, hormonal, and multifactorial.
• proliferation and inflammation probably are the most important. Histologically, it is characterized by thinning or ulceration of the bladder epithelial lining.
• Cystoscopic abnormalities in the bladder of patients with UCPPS include petechial hemorrhages called “glomerulations” and ulcers that extend into the lamina limba (Hunner’s ulcers).
• the most consistent histologic abnormalities include denudation or thinning of the bladder epithelium to 1-2 cell layers.
• UCPPS may be caused by an inhibition of normal bladder epithelial cell proliferation, resulting in a loss of epithelial barrier integrity with subsequent exposure of sensory nerve cells in the bladder wall to urinary constituents.
• This hypothesis has been supported by the recent identification of a glycosylated frizzled- related peptide inhibitor of cell proliferation from bladder epithelial cells of patients with UCPPS.
• This antiproliferative factor (APF) significantly inhibits bladder cell proliferation by regulating cell adhesion molecules and growth factor production.
• MS Multiple Sclerosis
• MS is an autoimmune disease diagnosed in 350,000 to 500,000 people in the United States. Multiple areas of inflammation and scarring of the myelin in the brain and spinal cord signify the disease. Patients with MS exhibit varying degrees of neurological impairment depending on the location and extent of the scarring of the myelin. Common symptoms of MS include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors, and depression. Current treatment of MS only alleviates symptoms or delays the progression of disability, and several new treatments for MS including stem cell transplantation and gene therapy are a conservatory. While anti-TNF antibodies have shown protective effects in experimental autoimmune encephalomyelitis (EAE), they aggravate the disease in MS patients, suggesting that inhibition of TNF-a alone is not sufficient.
• EAE experimental autoimmune encephalomyelitis
• AD Alzheimer’s disease
• PD Parkinson's disease
• AD is a brain disorder. It seriously affects a person’s ability to carry out daily activities. It involves the parts of the brain that control thought, memory, and language. About 4 million Americans, usually after age 60, are estimated to suffer from AD.
• PD is a progressive disorder of the central nervous system affecting over 1.5 million people in the United States. Clinically, the disease is characterized by a decrease in spontaneous movements, gait difficulty, postural instability, rigidity, and tremor. PD is caused by the degeneration of the pigmented neurons in the Substantia nigra of the brain, resulting in decreased dopamine availability. The causes of these neurodegenerative disorders are unknown, and there is currently no cure for the disease.
• Cytokines can be generally classified into 3 types: proinflammatory (IL-la, b, IL- 2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF-a, LT, LIF. Oncostatin, and IFNcla, b, g); anti-inflammatory (IL-4, IL-10, IL-11, W-13 and TGFB); and chemokines (IL- 8, Groa, MIP-1, MCP-1, ENA-78, and RANTES).
• proinflammatory IL-la, b, IL- 2, IL-3, IL-6, IL-7, IL-9, IL-12, IL-17, IL-18, IL-23, TNF-a, LT, LIF. Oncostatin, and IFNcla, b, g
• anti-inflammatory IL-4, IL-10, IL-11, W-13 and TGFB
• chemokines IL- 8, Groa, MIP-1, M
• pro-inflammatory cytokinines especially TNF-a. IL-Ib, and IL-6, as well as anti-inflammatory cytokine IL-10 appear to play an important role in the pathogenesis of various inflammatory-related diseases and therefore may serve as potential therapeutic targets.
• IL-10 has been shown to suppress elevated pro-inflammatory cytokine production both in vitro in LPMC cultures and in vivo in patients. Positive response of CD patients treated with IL-10 demonstrates that there might also be an imbalance between the production of pro- inflammatory and anti-inflammatory cytokines in CD.
• Meisoindigo is an indirubin derivative that has been used for the treatment of chronic myeloid leukemia (CML) in China with minor side effects.
• CML chronic myeloid leukemia
• Meisoindigo and its derivatives are active against solid tumors through their ability to inhibit cyclin-dependent kinases, induce cell differentiation and promote apoptosis.
• Meisoindigo has been shown to be effective in preventing cancer, treating cancer, and treating inflammatory-related diseases associated with pro-inflammatory cytokine expression, reduced expression of anti-inflammatory cytokines, or both.
• the crystalline forms of meisoindigo disclosed herein are stable under conditions of lighting, high temperature and high humidity.
• the crystalline forms of meisoindigo disclosed herein are also stable under conditions of grinding, pressure and hearing, which meets the production, transportation and storage requirements of drug products.
• the crystalline forms of meisoindigo disclosed herein are more excellent compared to other crystal forms in view of, for example, purity, handleability (lower hygroscopicity), fluidity, grindability, and/or quality control, and are useful as crystals appropriate for pharmaceutical formulation. These crystalline forms demonstrate excellent stability even in contact with heat, light, oxygen, humidity, or other molecules. Furthermore, the crystal forms of the present invention are excellent in filtration performance, drying characteristics, and fluidity, and can be produced in an industrially advantageous manner.
• the crystal forms of the present invention in which the amount of residual solvent is below the reference value described in the Guideline for Residual Solvents in ICH (International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use) guidelines, is safe as a medicament. Furthermore, the disclosed crystal forms have a relatively small electric charge amount and are easy to handle in the production and packing of medicaments.
• the crystal forms of the present invention have one or more beneficial properties, in particular the following advantages: improved stability, improved solubility and dissolution rates in water or in aqueous system(s), improved thermodynamic stability, and/or improved storage stability.
• the preparation processes disclosed herein are stable, repeatable and controllable, which makes them suitable for industrial production.
• Reaction Vessel the manufacturing is carried out in a 12 Liter round bottom flask with ports for a thermowell, a reflux condenser and charging reagents and solvents.
• Filtration Flask a 20 Liter Glass Filtration Flask with a side arm to connect to the vacuum.
• Tabletop Filter Funnel ⁇ a high-density polyethylene funnel measuring 10.25” inner diameter and 8” over all height and containing a fixed porous filter plate and fitted with a 12.7 mm vacuum connector.
• reaction mixture is heated to 85 to 95°C for 2 to 3 hours.
• reaction mixture is allowed to cool to 25 to 30°C and the precipitated product is filtered by suction.
• Recry stallized product is filtered by suction, washed with 0.75 L and 0.38 L portions of glacial acetic acid and dried at 50°C under vacuum.
• the inventors also disclose a N-methylisoindigo crystalline composition.
• N-methylisoindigo is a dark-red crystalline powder. The melting point of N methylisoindigo is between 235-237°C. N-methylisoindigo is sparingly soluble in acetone, chloroform, and ethanol. N-methylisoindigo is slightly soluble in water.
• N-methylisoindigo The structural elucidation and confirmation of N-methylisoindigo is carried out on the primary standard, batch SR-I 205a.
• the solid state of N-methylisoindigo is presented below (in the“Other Characteristics” Section).
• Elucidation of structure the structural elucidation and structure of the compound N-methylisoindigo are provided.
• the analytical techniques used for the structural elucidation are Infrared spectrophotometry, Nuclear magnetic resonance spectrometry, and Mass spectrometry. [00106] Infrared spectrum
• the melting point was obtained using a capillary tube-type melting point apparatus.
• the capillaries were 0.8-1.1 mm O.D., 90 mm long, sealed at one end.
• the melting temperature was measured with a calibrated electronic thermometer using a K-type thermocouple.
• the melting range should be 235°C - 237 °C, with a variation ⁇ 3 °C.
• Sample NAT-0601 is slightly more crystalline than the others, so that weaker peaks are more apparent, such as at the shoulders of the 17, 18 and 29° peaks.
• Sample NAT-0501 contains extra peaks, meaning an extra component is in the powder, in a small amount (e.g., several multiple, but minor peaks near 11, 16 and 23°). A possible explanation for this may be that Lot # 0501 was reworked. When lot # NAT-0501 was prepared, there was no recrystallization step and the purity was found to be less than 98%. A recrystallization step was added and the product obtained met the specification.
• FIG. 6 shows a detailed view of the peak selection analysis in program Jade, and the list of found 2Q values for all four samples are compiled in Table 2.
• Crystal Form I was analyzed for its particle size and distribution. Five batches were tested using a Malvern Mastersizer 2000 (MIIA14730, Malvern, UK).
• FIG. 11 shows examples of particle distribution of the Crystal Form I of the compound.
• Crystal Form I has a uniform particle size with an ideal distribution (see FIG. 11). This uniform particle size facilitates formulation of Crystal Form I into a pharmaceutical composition. The uniform particle size also indicates the reproducibility of the process for forming Crystal Form I.
• Sample #7 recrystallization in methanol/water: Three hundred (300) mg of newly synthesized N-methylisoindigo was heated to 80°C to which 80ml of methanol was added, and heated under reflux until it became clear. Two hundred (200) ml of water was then slowly added to the solution with heat reflux. The solution became cloudy again and was heated under reflux continuously until it became clear again, and then filtered when it was still hot. The solution stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• Sample #2 recrystallization in methanol: Three hundred (300) mg of newly synthesized N-methylisoindigo was heated to 80°C to which 80ml of methanol was added, and heated with reflux until it became clear. The solution was then filtered when it was still hot, stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• Sample #3 recrystallization in ethyl acetate and ligroin: One hundred (100) mg of newly synthesized N-methylisoindigo was heated to 80°C to which 40ml of ethyl acetate was added under heat reflux until it became clear. One hundred twenty (120) ml of ligroin was then slowly added to the solution. The solution became cloudy and was then heated under reflux until it became clear again. The solution was filtered when it was still hot, stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• Sample #4 recrystallization in ethyl acetate: One hundred (100) mg of newly synthesized N-methylisoindigo was heated to 80° C to which 30ml of ethyl acetate was added under heat reflux until it became clear. The solution was then filtered when it was still hot, stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• Sample #5 recrystallization in ethyl alcohol and water: One hundred (100) mg of newly synthesized N-methylisoindigo was heated to 80°C to which 30 ml of ethyl alcohol was added under heat reflux until it became clear. Sixty (60) ml of distilled water was then added to the solution. The solution became cloudy temperately and then clear again. The solution was filtered when it was still hot, stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• Sample #6 recrystallization in ethyl alcohol: One hundred (100) mg of newly synthesized N-methylisoindigo was heated to 80°C to which 30 ml of ethyl alcohol was added under heat reflux until it became clear. The solution was filtered when it was still hot, stood and cooled down to room temperature. The compound gradually precipitated and was then filtered and dried.
• sample #1 to #6 are powder like; sample #2 and #4 are arborescent whereas sample #3 and #6 are acicular. Both arborescent and acicular are known to have a poor flow rate and are, thus, not ideal for pharmaceutical formulations. Importantly, all these crystalline forms showed lower milting points (i.e., 225.4° to 229.5°C as compared with 235.2° to 236.6° C disclosed above for Crystal Form I) demonstrating these crystal forms are different from Crystal Form I.
• FIGs. 10A-10G show the X-ray spectrum (PXRD) of the 6 crystalline samples. None of them have repeated each other. PXRD suggests that sample 1-6 were mixtures of multiple crystalline forms.
• Sample 2 and sample 4 showed fewer narrow peaks and fewer high peaks, indicating the crystalline forms not only had larger particle sizes but were mixtures of crystal types.
• Sample 3 and 6 showed peaks that were not only narrow but relatively impure compared to the other samples. Many peaks from these samples overlapped each other, indicating a typical mixture of crystal types of meisoindigo. The number of crystal types in Sample 3 and 6 were much more than that of the other 4 samples. This indicates that many crystalline forms were quickly produced under the given re-crystalline conditions, and the crystalline forms might contain the solvent. These results suggest that the re-crystalline conditions for Sample 3 and 6 were not suitable to yield a uniform crystalline powder.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Oncology (AREA)
• Hematology (AREA)
• Dermatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (11)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=70974812

Family Applications (1)

Country Status (9)

Cited By (1)

Citations (3)

Family Cites Families (4)

• 2019
  • 2019-11-21 JP JP2021532308A patent/JP2022511554A/ja active Pending
  • 2019-11-21 US US17/298,528 patent/US20220009889A1/en not_active Abandoned
  • 2019-11-21 CN CN202410495669.6A patent/CN118515598A/zh active Pending
  • 2019-11-21 MX MX2021006464A patent/MX2021006464A/es unknown
  • 2019-11-21 EP EP19892926.7A patent/EP3891141A4/en active Pending
  • 2019-11-21 CA CA3121726A patent/CA3121726A1/en active Pending
  • 2019-11-21 KR KR1020217021317A patent/KR20210102335A/ko not_active Ceased
  • 2019-11-21 CN CN201980090936.9A patent/CN113365990A/zh active Pending
  • 2019-11-21 WO PCT/US2019/062704 patent/WO2020117487A1/en not_active Ceased
• 2021
  • 2021-06-03 IL IL283703A patent/IL283703A/en unknown
• 2024
  • 2024-08-22 JP JP2024141101A patent/JP2024170448A/ja active Pending
  • 2024-11-21 US US18/955,955 patent/US20250084035A1/en active Pending

Patent Citations (3)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events